Related Experiment Video

Updated: Apr 4, 2026

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
08:56

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions

Published on: November 30, 2022

3.6K

Drug delivery and therapeutic impact of extended-release acetylsalicylic acid

Kevin P Bliden1, Jeff Patrick2, Andrew T Pennell2

  • 1Sinai Center for Thrombosis Research, Baltimore, MD, USA.

Future Cardiology
|September 11, 2015
PubMed

Insights

Extended-release aspirin (ER-ASA) offers 24-hour anti-thrombotic coverage for cardiovascular event prevention. This new formulation ensures sustained antiplatelet effects with once-daily dosing, improving upon traditional aspirin.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Drug Delivery Systems

Background:

  • Current guidelines recommend low-dose acetylsalicylic acid (ASA) for secondary cardiovascular event prevention.
  • Traditional ASA formulations may not provide continuous 24-hour anti-thrombotic protection.
  • Patients at high risk require sustained protection against recurrent cardiovascular events.

Purpose of the Study:

  • To evaluate a novel extended-release acetylsalicylic acid (ER-ASA) formulation.
  • To assess the pharmacokinetic and pharmacodynamic profile of ER-ASA for 24-hour anti-thrombotic coverage.
  • To compare the efficacy and safety of ER-ASA with immediate-release ASA.

Main Methods:

  • Pharmacokinetic analysis of ER-ASA absorption and release.
  • Assessment of antiplatelet effects over a 24-hour period.
  • Evaluation of the safety profile of ER-ASA in patients.

Main Results:

  • ER-ASA demonstrates slower absorption and prolonged release compared to immediate-release ASA.
  • The extended-release formulation provides sustained antiplatelet effects for 24 hours.
  • ER-ASA exhibits a favorable safety profile with minimized systemic absorption.

Conclusions:

  • ER-ASA offers a promising alternative for 24-hour anti-thrombotic coverage in secondary cardiovascular prevention.
  • The sustained release profile of ER-ASA enhances therapeutic benefits for high-risk patients.
  • ER-ASA provides a safe and effective option for once-daily antiplatelet therapy.

Keywords:
Durlazaacetylsalicylic acidantiplateletcardiovascular diseasediabetesextended-releasemicrocapsulesecondary preventionthrombosis

More Related Videos

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

684
Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions07:49

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

12.0K

Related Concept Videos

Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
148
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
172
Modified-Release Drug Delivery Systems: Influencing Factors01:20

Modified-Release Drug Delivery Systems: Influencing Factors

Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
140
Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
254
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
220
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
308